Skip to main content

Table 5 Factors associated with hypertension

From: HIV infection, and overweight and hypertension: a cross-sectional study of HIV-infected adults in Western Kenya

 

N

n

%

OR

95% CI

P value

aOR

95% CI

P value

Age category

 18–29

33

3

9.1

1.00

   

1.00

   

 30–39

104

8

7.7

0.83

0.21

3.34

0.797

0.75

0.18

3.08

0.308

 40 and older

113

17

15.0

1.77

0.48

6.45

0.387

1.93

0.51

7.23

0.952

Sex

 Male

81

8

9.9

1.00

   

1.00

   

 Female

169

20

11.8

1.22

0.51

2.91

0.646

1.23

0.51

2.99

0.645

Marital status

 Single

7

0

0.0

1.00

   

1.00

   

 Married

154

17

11.0

   

0.999

   

0.999

 Divorced

10

0

0.0

1.00

  

1.000

   

1.000

 Widowed

79

11

13.9

1.00

  

0.999

   

0.999

Education level

 Low education

96

13

13.5

1.00

   

1.00

   

 Complete primary

116

11

9.5

0.66

0.28

1.56

0.355

0.59

0.23

1.47

0.260

 Complete secondary or higher

38

4

10.5

0.75

0.22

2.46

0.637

0.42

0.11

1.71

0.229

Occupation

 At home

31

2

6.5

1.00

   

1.00

   

 Working outside

48

4

8.3

1.31

0.22

7.66

0.759

1.35

0.22

8.11

0.741

 Working inside

135

17

12.6

2.08

0.45

9.55

0.342

1.98

0.42

9.35

0.387

 Others

36

5

13.9

2.33

0.42

13.01

0.332

1.79

0.31

10.49

0.516

SES

 Poorest

63

7

11.1

1.00

   

1.00

   

 Poor

62

4

6.5

0.55

0.15

1.98

0.363

0.51

0.14

1.86

0.308

 Less poor

62

7

11.3

1.01

0.33

3.09

0.975

0.96

0.31

2.98

0.952

 Rich

62

10

16.1

1.53

0.54

4.33

0.414

1.78

0.61

5.17

0.289

Physical activity level

 Inactive

11

2

18.2

1.00

   

1.00

   

 Minimally active

22

2

9.1

0.45

0.05

3.71

0.459

0.46

0.05

4.01

0.482

 HEPA active

214

24

11.2

0.56

0.11

2.78

0.486

0.46

0.08

2.43

0.364

Chai per day

 0–1 cup

20

0

0.0

1.00

   

1.00

   

 2 cups

58

1

1.7

   

0.998

   

0.998

 3 cups or more

172

27

15.7

   

0.997

   

0.998

Soda per week

 None

125

19

15.2

1.00

   

1.00

   

 Once

64

4

6.3

0.37

0.12

1.14

0.085

0.41

0.13

1.29

0.130

 Twice or more

61

5

8.2

0.49

0.17

1.41

0.188

0.57

0.20

1.66

0.311

Ugali per day

 Quarter a plate

184

24

13.0

1.00

   

1.00

   

 Half a plate

55

4

7.3

0.52

0.17

1.57

0.250

0.50

0.16

1.54

0.230

 3 quarters a plate or more

8

0

0.0

   

0.998

   

0.998

Alcohol

 No

222

24

10.8

1.00

   

1.00

   

 Yes

24

3

12.5

1.17

0.32

4.24

0.802

1.35

0.35

5.23

0.661

Smoke

 No

241

28

11.6

1.00

   

1.00

   

 Yes

9

0

0.0

   

0.998

   

0.998

Overweight/obesity

 No

208

21

10.1

1.00

   

1.00

   

 Yes

42

7

16.7

1.78

0.70

4.51

0.223

1.95

0.74

5.13

0.173

Abdominal obesity

 No

137

12

8.8

    

1.00

   

 Yes

113

16

14.2

    

1.71

0.66

4.42

0.261

ART duration

 0–364 days

14

2

14.3

1.00

   

1.00

   

 365 days and more

236

26

11.0

1.71

0.77

3.80

0.182

0.51

0.10

2.59

0.424

CD4 counts (cells/μl)

 < 200

30

3

10.0

1.00

   

1.00

   

 200–499

113

13

11.5

1.17

0.31

4.40

0.816

1.51

0.38

5.95

0.555

 ≥ 500

105

12

11.4

1.16

0.31

4.41

0.826

1.62

0.40

6.56

0.495

On PI

 No

214

26

12.1

1.00

   

1.00

   

 Yes

35

2

5.7

0.43

0.09

1.93

0.276

0.39

0.08

1.81

0.234

PI duration

 0–359 days

7

0

0.0

1.00

   

1.00

   

 540 days and more

27

2

7.4

   

0.998

   

0.999

WHO stage

 1

51

10

19.6

1.00

   

1.00

   

 2

71

10

14.1

0.67

0.25

1.75

0.414

0.52

0.18

1.44

0.211

 3

96

6

6.3

0.27

0.09

0.80

0.018

0.18

0.05

0.58

0.004

 4

29

2

6.9

0.30

0.06

1.49

0.143

0.16

0.02

0.87

0.034

OI history

 No

204

21

10.3

1.00

   

1.00

   

 Yes

44

7

15.9

1.64

0.65

4.15

0.290

1.52

0.57

4.00

0.396

  1. N number of study participants, n number of elements in a sample, OR odds ratio, 95% CI 95% confidential interval, aOR adjusted odds ratio, P value probability value, HEPA health-enhancing physical activity, ART anti-retroviral therapy, PI protease inhibitor, WHO stage WHO clinical staging of HIV/AIDS for adults and adolescents, OI opportunistic infection